MicroRNA-202 suppresses glycolysis of pancreatic cancer by targeting hexokinase 2

© The author(s)..

Purpose: Various studies have identified miR-202 critically participated in the development of different cancers. However, the potential mechanisms underlying the carcinogenesis of pancreatic cancer (PC) still remains elusive. Methods: In the study, cell proliferation assay, colony formation assay, EdU incorporation assay, Luciferase reporter assay, lactate production, glucose consumption assay, real-time PCR and western blot were used to investigate the mechanism of hexokinase 2 (HK2) regulated by miR-202 in pancreatic cancer in vitro and in vivo. Results: Here we found that miR-202 was decreased in the PC tissues, and its low expression was correlated with a poor prognosis of PC patients. Overexpression of miR-202 in PC cells reduced cell proliferation and tumorigenesis by impairing glycolysis, while downregulation of miR-202 promoted the cells proliferative capacity. Mechanically, we demonstrated that HK2, an enzyme that catalyzes the irreversible rate-limiting step of glycolysis, as the direct target of miR-202. Overexpression of miR-202 suppressed both the mRNA and protein levels of HK2, whereas re-introduction of HK2 abrogated miR-202-mediated glycolytic inhibition. In addition, the expression of miR-202 was negatively associated with HK2 level in a cohort of PC tissues. Conclusion: Our findings validate the mechanism that miR-202 reprograms the metabolic process to promote PC progression, thus providing potential prognostic predictors for PC patients.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:12

Enthalten in:

Journal of Cancer - 12(2021), 4 vom: 06., Seite 1144-1153

Sprache:

Englisch

Beteiligte Personen:

Wang, Shuang-Jia [VerfasserIn]
Li, Xiu-Dong [VerfasserIn]
Wu, Lu-Peng [VerfasserIn]
Guo, Ping [VerfasserIn]
Feng, Liu-Xing [VerfasserIn]
Li, Bin [VerfasserIn]

Links:

Volltext

Themen:

Glycolysis
Hexokinase 2
Journal Article
MiR-202
Pancreatic cancer

Anmerkungen:

Date Revised 15.01.2021

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.7150/jca.43379

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM320056961